lapatinib has been researched along with Inflammatory Breast Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Corral de la Fuente, E; Fernández Abad, M; Martin Huertas, R; Martínez Jáñez, N; Serrano Domingo, JJ | 1 |
| Aldrich, AJ; Allensworth, JL; Devi, GR; Ingram, SM; Sexton, JZ; Smith, GR; Williams, KP | 1 |
| Bessonov, AA; Bozhok, AA; Manikhas, AG; Nikolaev, KS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Downing, SR; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ | 1 |
| Bertucci, F; Gonçalves, A; Monneur, A; Viens, P | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Crane, K | 1 |
| Bartlett, J; Bogaerts, J; Bonnefoi, H; Cameron, D; Debled, M; Fiche, M; Fournier, M; Koch, KM; Marreaud, S; Nobahar, M; Pierga, JY; Zaman, K; Zimmer, A | 1 |
| Alvarez, RH; Blackwell, KL; Cristofanilli, M; Gladkov, O; Gomez, HL; Johnston, SR; Manikhas, A; Ranganathan, S; Redhu, S; Rubin, SD; Safina, S; Shao, Z; Trudeau, ME | 1 |
1 review(s) available for lapatinib and Inflammatory Breast Cancer
| Article | Year |
|---|---|
[Systemic treatments of inflammatory breast cancer: an overview].
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Trastuzumab | 2014 |
3 trial(s) available for lapatinib and Inflammatory Breast Cancer
| Article | Year |
|---|---|
[HER2-positive breast cancer: standard and double targeted therapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids | 2013 |
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Female; Humans; Indazoles; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
5 other study(ies) available for lapatinib and Inflammatory Breast Cancer
| Article | Year |
|---|---|
Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lapatinib; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; High-Throughput Screening Assays; Humans; Inflammatory Breast Neoplasms; Lapatinib; Quinazolines; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2014 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |